Targeting the RNA epitranscriptome
SACRA Therapeutics pioneers novel therapeutic strategies based on selective targeting of RNA modifying proteins for treating incurable solid and hematological cancers.
Our journey so far
Discovery of the role of RNA modifiers in cancer
Guzzi et. al; Cell, 2018
First drug discovery plans made
Received an LU innovation seed grant and a Novo Nordisk Pioneer Innovator grant.
Dedication. Expertise. Passion.
SACRA is a collaboration between experts for drug discovery, clinical oncology and epitranscriptomics. Our focus is “having the end in mind”-being guided by what brings benefits to the patients, at the same time realizing the potential of a novel therapeutic paradigm.
News and Events
Meet us at the Nordic Life Science days 2023!
29-30 Copenhagen, Denmark
c/o Red Glead Discovery AB
223 81 Lund
©2022 SACRA Therapeutics